Insmed Incorporated (INSM) Q3 2026 earnings results
Insmed Incorporated (INSM) reported Q3 2026 results on Oct 29, 2026, 7:01:15 AM ET: GAAP EPS -$0.46 vs. -$0.38 expected (miss by 21.5%); revenue $524.43M vs. $499.48M expected (beat by 5.0%). Outlook: The company raised its full-year 2026 revenue guidance for BRINSUPRI to $1.35 billion to $1.4 billion and for ARIKAYCE to $460 million to $470 million.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | -$0.46 | -$0.38 | Miss by 21.5% |
| Revenue | $524.43M | $499.48M | Beat by 5.0% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Oct 29, 2026, 7:01:15 AM ET. Nexqual published them 91 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): GAAP diluted EPS was -$0.46 vs. -$1.75 (+73.7%).
Stock reaction
The results came out before the market opened. INSM closed at $111.59 on October 29, 2026, up 15.1% from its $96.98 close on October 28, 2026 before the results.
Questions and answers
Did Insmed Incorporated beat earnings expectations?
No. Insmed Incorporated reported GAAP EPS of -$0.46 against an average analyst estimate of -$0.38 (miss by 21.5%), and revenue of $524.43M against $499.48M expected (beat by 5.0%).
What were Insmed Incorporated's Q3 2026 earnings and revenue?
GAAP diluted EPS of -$0.46 and revenue of $524.43M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): GAAP diluted EPS was -$0.46 vs. -$1.75 (+73.7%).
When did Insmed Incorporated report Q3 2026 earnings?
Oct 29, 2026, 7:01:15 AM ET, in an SEC 8-K filing (Item 2.02).
How did INSM stock react to the earnings?
The results came out before the market opened. INSM closed at $111.59 on October 29, 2026, up 15.1% from its $96.98 close on October 28, 2026 before the results.
What did Insmed Incorporated say about its outlook?
The company raised its full-year 2026 revenue guidance for BRINSUPRI to $1.35 billion to $1.4 billion and for ARIKAYCE to $460 million to $470 million.
More on INSM
INSM stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings October 29, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built October 29, 2026 at 23:08 UTC. Not investment advice.
Data source: Nexqual. Last updated: October 29, 2026 at 23:08 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt